Summary
The feasibility of techniques developed for isolating and culturing human mammary epithelial cells of malignant origin was confirmed in 136 primary breast cancers, 116 hypodermal metastases, and 8 metastatic lymph nodes. In 115 (84%) primary breast cancers and in 81 (70%) hypodermal recurrences we observed a goodin vitro cellular proliferation. These proliferating cells, at the second passage, were used for a clonal assay suitable for quantitating drug sensitivity. With this clonal assay median cloning efficiencies of 14% and 6% were obtained respectively in primaries and in skin recurrences. We examined thein vitro response to different drugs and confirmed the test's ability to detect heterogeneity in response to same drugs (doxorubicin, 4′-epidoxorubicin, vinblastine, cis platinum, and idarubicinol) among the different breast carcinoma cultures as well as heterogeneity among subpopulations within a single carcinoma.
This is a preview of subscription content, log in via an institution to check access.
References
Jensen EV: Hormone dependence of breast cancer. Cancer 47: 2319–2326, 1981
Seibert K, Lippman ME: Hormone receptors in breast cancer. In: Baum E (ed) Clinics in Oncology. WB Saunders, London, 1982, pp 735–794
Moot SK, Peters GN, Cheek JH: Tumor hormone receptor status and recurrences in premenopausal node negative breast carcinoma. Cancer 60: 382–385, 1987
McGuire WL: Prognostic factors for recurrence and survival. Breast Cancer Res Treat 10: 5–9, 1987
Gentili C, Sanfilippo O, Silvestrini R: Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer 48: 974–979, 1981
Meyer JS, Friedman E, McCrate M, Bauer WC: Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51: 1879–1886, 1983
Silvestrini R, Daidone MG, Gasparini G: Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 56: 1982–1987, 1985
Salmon SE, Hamburger AW, Soehnlein BJ, Durie BGM, Alberts DS, Moon TE: Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 298: 1321–1327, 1978
Dittrich Ch, Jakesz R, Wrba F, Havelec L, Haas O, Spona J, Holzner H, Kolb R, Moser K: The human tumour cloning assay in the management of breast cancer patients. Br J Cancer 52: 197–203, 1985
Weisenthal LM, Lippman ME: Clonogenic and nonclonogenicin vitro chemosensitivity assays. Cancer Treat Rep 69: 615–632, 1985
Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, Mattox ED, Page CP, Cruz AB, Sandbach F: Prospective clinical trial of human tumor cloning system. Cancer Res 43: 1926–1931, 1983
Bertelsen CA, Sondak VK, Mann BD, Korn EL, Kern DH: Chemosensitivity testing of human solid tumors. Cancer 53: 1240–1245, 1984
Salmon SE: Human tumor colony assay and chemosensitivity testing. Cancer Treat Rep 68: 117–125, 1984
Silvestrini R, Sanfilippo O, Daidone MG, Zaffaroni N: Predictive relevance for clinical outcome ofin vitro sensitivity evaluated through antimetabolic assay. In: Hofmann V, Martz G (eds) Predictive Drug Testing on Human Tumor Cells. Springer-Verlag, Berlin, 1984, pp 140–150
Daidone MG, Silvestrini R, Sanfilippo O, Zaffaroni N, Varini M, De Lena M: Reliability of anin vitro short-term assay to predict the drug sensitivity of human breast cancer. Cancer 56: 32–37, 1985
Smith HS, Lan S, Ceriani R, Hackett AJ, Stampfer MR: Clonal proliferation of cultured nonmalignant and malignant human breast epithelia. Cancer Res 41: 4637–4643, 1981
Smith HS, Hackett AJ, Lan S, Stampfer MR: Use of an efficient method for culturing human mammary epithelial cells to study adriamycin sensitivity. Cancer Chemother Pharmacol 6: 237–244, 1981
Smith HS, Lippman ME, Hiller AJ, Stampfer MR, Hackett AJ: Response to doxorubicin of cultured normal and cancerous human mammary epithelial cells. J Natl Cancer Inst 74: 341–347, 1985
Stampfer MR, Hallowes RC, Hackett AJ: Growth of normal human mammary cells in culture.In Vitro 16: 414–425, 1980
Agresti R, Alzani R, Andreola S, Bedini V, Giani S, Ménard S, Rilke F, Colnaghi MI: Histopathological characterization of a novel monoclonal antibody, MLuC1, reacting with lung carcinomas. Tumori 74: 401–410, 1988
Ménard S, Tagliabue E, Canevari S, Fossati G, Colnaghi MI: Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. Cancer Res 43: 1295–1300, 1983
Porro G, Agresti R, Da Dalt MG, Ménard S, Colnaghi MI: Correlation between the expression of breast carcinoma markers defined by monoclonal antibodies and tumor progression. (Abstact). Biennial International Breast Cancer Research Conference, Miami, 1987
Cordell JL, Falini B, Erber WN: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32: 219–229, 1984
Stampfer MR, Hackett AJ, Hancock MC, Leung JP, Edgington TS, Smith HS: Growth of human mammary epithelium in culture and expression of tumor specific properties. Cold Spring Harbor Symposium on Cellular Proliferation 9: 819–929, 1982
Stampfer MR, Vlodaky I, Smith HS, Ford R, Becker FF, Riggs J: Fibronectin production by human mammary cells in culture. J Natl Cancer Inst 67: 253–261, 1981
Cerosimo RJ, Hong WK: Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 4: 425–439, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zoli, W., Volpi, A., Bonaguri, C. et al. An efficient method for culturing human breast carcinoma to evaluate antiblastic drug activityin vitro: Experience on 136 primary cancers and on 116 recurrences. Breast Cancer Res Tr 17, 231–238 (1991). https://doi.org/10.1007/BF01806372
Issue Date:
DOI: https://doi.org/10.1007/BF01806372